Bank of New York Mellon’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.47M | Buy |
1,081,203
+217,979
| +25% | +$1.1M | ﹤0.01% | 2212 |
|
|
2025
Q1 | $4.57M | Buy |
863,224
+12,588
| +1% | +$66.6K | ﹤0.01% | 2259 |
|
|
2024
Q4 | $5.75M | Sell |
850,636
-75,482
| -8% | -$510K | ﹤0.01% | 2205 |
|
|
2024
Q3 | $6.1M | Sell |
926,118
-134,686
| -13% | -$888K | ﹤0.01% | 2196 |
|
|
2024
Q2 | $7.96M | Buy |
1,060,804
+178,994
| +20% | +$1.34M | ﹤0.01% | 2085 |
|
|
2024
Q1 | $8.79M | Buy |
881,810
+48,535
| +6% | +$484K | ﹤0.01% | 2025 |
|
|
2023
Q4 | $8.22M | Buy |
833,275
+199,265
| +31% | +$1.96M | ﹤0.01% | 2087 |
|
|
2023
Q3 | $4.85M | Buy |
634,010
+37,317
| +6% | +$285K | ﹤0.01% | 2332 |
|
|
2023
Q2 | $4.46M | Buy |
596,693
+67,536
| +13% | +$504K | ﹤0.01% | 2384 |
|
|
2023
Q1 | $3.53M | Buy |
529,157
+23,710
| +5% | +$158K | ﹤0.01% | 2491 |
|
|
2022
Q4 | $3.9M | Buy |
505,447
+1,506
| +0.3% | +$11.6K | ﹤0.01% | 2477 |
|
|
2022
Q3 | $5.36M | Buy |
503,941
+104,588
| +26% | +$1.11M | ﹤0.01% | 2258 |
|
|
2022
Q2 | $3.25M | Buy |
399,353
+25,653
| +7% | +$209K | ﹤0.01% | 2551 |
|
|
2022
Q1 | $2.68M | Buy |
373,700
+6,294
| +2% | +$45.1K | ﹤0.01% | 2780 |
|
|
2021
Q4 | $6.29M | Buy |
367,406
+263,379
| +253% | +$4.51M | ﹤0.01% | 2343 |
|
|
2021
Q3 | $2.39M | Buy |
104,027
+30,633
| +42% | +$705K | ﹤0.01% | 2874 |
|
|
2021
Q2 | $2.68M | Buy |
+73,394
| New | +$2.68M | ﹤0.01% | 2814 |
|